<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of Burkitt cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">FABL3</z:e>) [1] in a patient 7 years after successful treatment of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) by combined modality (chemotherapy and radiotherapy) therapy is described </plain></SENT>
<SENT sid="1" pm="."><plain>The B-cell nature of the leukemic blasts is shown by immunologic surface marker studies </plain></SENT>
<SENT sid="2" pm="."><plain>While L3 <z:hpo ids='HP_0001909'>leukemia</z:hpo> is very rarely seen following therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of small noncleaved cells (LSNC)--resembling the <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumor</z:e>--is more common in this setting </plain></SENT>
</text></document>